SYRE

93.4704.26%
KT

Keith T. Flaherty

Founder & Member of Corporate Advisory Board

Dr. Keith T. Flaherty serves as President & Member of Advisory Council of American Association For Cancer Research. Dr. Flaherty is Member of Scientific Advisory Board of NaNotics LLC. He serves as Venture Partner of Catalio Capital Management, LP. He is Scientific Co-Founder of Predicta Biosciences, Inc. Dr. Flaherty is Co-Founder of Loxo Oncology, Strata Oncology, X4 Pharmaceuticals, Apricity, C-Reveal and Scorpion Therapeutics. He is Co-Founder and Co-Chair of the Medical Advisory Board of Apricity Health, LLC. He is Academic Founder and Director at Scorpion Therapeutics, Inc. and has been its Member of Clinical Scientific Advisory Board since November 2022. He is Founder of X4 Pharmaceuticals, Inc. and has been a Member of Corporate Advisory Board at X4 Pharmaceuticals Inc. since April 4, 2016. He is a Co-Founder of Strata Oncology, Inc. and serves as its Director. He has been Executive Director at C-Reveal Therapeutics LLC. Dr. Flaherty serves as Board of Directors at Scorpion Therapeutics, Strata Oncology, Clovis Oncology. He is Director of Clinical Research and Richard Saltonstall Chair in Oncology, MGH Cancer Center. He has served as a Director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital Cancer Center since 2012. He has served as Director of Clinical Research at the Massachusetts General Hospital since 2014. He serves as Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital. He is Professor of Medicine, Harvard Medical School. He serves as an Associate Professor of Medicine at Harvard Medical School since October 2015. Dr. Flaherty is a Clinical Oncologist. He focuses on Oncogene targeted therapy, cancer immunotherapy, early drug development. He is Member of Scientific Advisory Board of Tasca Therapeutics Corp. He is Member of Scientific Advisory Board of Kanvas Biosciences, Inc. from July 2025. He serves as Member of Scientific Advisory Board at Biostate AI, Inc. He serves at Scientific Advisory Board at PIC Therapeutics, Apricity, Tvardi, ALX Oncology, xCures, Monopteros, Vibliome, Soley Therapeutics, Quanta Therapeutics and intrECate. He is Member of Scientific Advisory Board of Soley Therapeutics, Inc since 2023. He serves as Scientific Advisory Board Member at Vibliome Therapeutics, Inc. He has been Chair of Clinical Advisory Board at Monopteros Therapeutics Inc. He serves as Member of Scientific Advisory Board of Alterome Therapeutics, Inc. since January 2023. He has been a Member of Scientific Advisory Board at Sporos Bioventures since January 2022. He had been Chairman of Scientific Advisory Board at xCures, Inc until July 2026. He serves as a Member of Advisory Board at TransCode Therapeutics, Inc. He serves as the Chairman of Scientific Advisory Board at ALX Oncology Holdings Inc. since October 2020. Dr. Flaherty serves as Scientific Advisory Board Member of Tvardi Therapeutics, Inc. In April 2013, he was appointed as the ECOG Deputy Chair for Biomarker Science. Dr. Flaherty is also the Deputy Chair for Biomarker Sciences. He serves as a Senior Editor for Clinical Cancer Research. He serves as Member of Oncology Board of Advisors at Checkmate Pharmaceuticals, Inc. In September 2018, Dr. Flaherty joined the National Cancer Institute Board of Scientific Advisors. Dr. Flaherty has been a Member of Scientific Advisory Board at Kinagen, Inc. since May 2010. He serves as Member of Scientific Advisory Board of PIC Therapeutics Inc. He serves as Chair of the Clinical Advisory Board at Viralytics Limited. He serves as Member of Oncology Scientific Advisory Board at Asana BioSciences, LLC. He has been a Member of Scientific Advisory Board at Spyre Therapeutics, Inc. since September 2016. He serves as a Member of Scientific Advisory Board of Raze Therapeutics, Inc. He serves as a Member of Scientific Advisory Board of Exosome Diagnostics, Inc. Dr. Flaherty joined the American Association for Cancer Research Board of Directors in 2019. He serves as a Member of the editorial boards for Cancer Discovery, Journal of Medicine. He serves as Editor-in-Chief for Clinical Cancer Research. He serves on the Board of Directors of the American Association for Cancer Research. He is the Principal investigator of the National Cancer Institute MATCH trial. Dr. Flaherty served as an Independent Director of Kinnate Biopharma Inc. from December 2019 to April 3, 2024. He served as its Member of Scientific Advisory Board until April 3, 2024. Dr. Flaherty had been Director at Checkmate Pharmaceuticals, Inc. from March 2019 to May 31, 2022. He served as Member of Scientific Advisory Board at OnKure Therapeutics, Inc. until December 2024. He was Member of Scientific Advisor Board at Neon Therapeutics, Inc until October 2019. He served as Chairman of the Scientific Advisory Board at Loxo Oncology, Inc. since October 3, 2013. He was its Director from September 2013 to February 15, 2019. He served on the Board of Directors through the acquisition by Eli Lilly in 2019. He served as a Member of Scientific Advisory Board at Viralytics Limited since November 2013. He served as a Member of Oncology Advisory Board at Tioma Therapeutics, Inc. He was a Member of Scientific Advisory Board at Oncoceutics, Inc. He served as a Member of Scientific Advisory Board at CollabRx, Inc. He has been a Member of Scientific Advisory Board at Parabilis Medicines, Inc. Dr. Flaherty has a Bachelor of Science in neurobiology from Yale University in 1993 and a Doctor of Medicine from The Johns Hopkins School of Medicine in 1997. He completed a Residency in Medicine, at Brigham and Women’s Hospital in Boston. He completed a Fellowship in Medical Oncology at the Hospital of the University of Pennsylvania.

Positions